Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > November 25, 2022
Daily News
November 25, 2022
- Japan Approves Label Expansion for Enhertu, TS-1, and More
November 25, 2022
- PeptiDream to Codevelop Lilly's Alzheimer’s Diagnostic Tauvid in Japan
November 25, 2022
- Opdivo Secures Top-Selling Title, Veklury Runner Up in July-September: IQVIA
November 25, 2022
- Upper House Health Committee OKs Bill to Amend Infectious Disease Act
November 25, 2022
- LDP Pharma Study Group Calls for Careful Discussions on Off-Year Plan: Proposal
November 25, 2022
- Japan Infectious Diseases Association Updates Guidelines after Xocova Approval
November 25, 2022
- Shionogi Chief Defends Xocova Data, Eager to Prove Benefits in Clinical Settings
November 25, 2022
- AbbVie Japan Launches Maviret for Age 3 and Older
November 25, 2022
- Takeda’s Dengue Vaccine Bags Fast-Track Tag in US
November 25, 2022
- Fujifilm to Build Cell Culture Media Manufacturing Center in US
November 25, 2022
- Chugai to Transfer Bonviva Marketing Rights to Taisho
November 25, 2022
- FunPep’s Functional Peptide Fails in Japan PIII Study for Skin Ulcers
November 25, 2022
- Mitsubishi Tanabe, Sumitomo in Antibiotics Collabs with GARDP
November 25, 2022
- The Pros and Cons of Working from Home in 2022
November 25, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…